Investors
Building the Clinical Data Automation Layer.
ClinDaddy addresses labor-intensive clinical-data workflows at multiple points in the trial lifecycle. The initial wedge is a single, well-bounded deliverable; the expansion follows the data downstream.

Investment thesis
A narrow wedge, then the same model downstream.
Initial wedge
FlashEDC
Protocol to eCRFs, then EDC data collection.
The narrowest, most repeatable problem in the lifecycle: turning a protocol into a review-ready study design, then capturing data against it. Clear input, reviewable output, measurable cost today.
Downstream expansion
FlashAnalysis
Clinical data → SDTM → ADaM → TLFs → submission.
The same data continues into standards, analysis, QC and submission artifacts. Each stage is effort-heavy and specification-driven, which is what makes it automatable — and each can be sold as one deliverable.
Go-to-market
Go-to-market
Land with a deliverable, expand with a licence, scale through partners.
A fixed-price SDTM/ADaM/TLF package or one FlashEDC study build is the first sale. The per-study software licence follows, and CROs and biostatistics firms can white-label FlashAnalysis output. Discounted pilots are available for the first customers.
Long-term platform
One canonical study model, projected into the systems a trial runs on.
The protocol is read once into a system-neutral study model. Today it projects into EDC and the downstream submission chain. RTSM is in development for 2027; patient-facing capture and trial operations follow, toward an AI CRO.
- Protocol
- eCRFs
- EDC
- SDTM
- ADaM
- TLFs
Current technology position
Finished products, available for a live demo.
- FlashAnalysis~2,500 automated tests
- The current FlashAnalysis codebase is covered by approximately 2,500 automated tests. Passing tests describe code health, not commercial traction.
- FlashEDCStudy build + EDC
- FlashEDC runs protocol analysis, eCRF design and its own EDC data collection. The products are demo-ready today.
Engineering metrics describe code health and coverage. They are not evidence of commercial traction, and we do not present them as such.
Diligence
The questions we expect, answered in the open.
What problem is being solved?
Manual translation work across the clinical-data lifecycle: protocol to study design, collected data to standards, standards to analysis, analysis to submission artifacts.
Why is the problem valuable?
The work is high-volume, high-consequence and repeated per study by every sponsor and CRO. Errors are expensive and late-stage corrections are more expensive still.
Why is this difficult?
Clinical work cannot be fully autonomous. It requires deterministic execution, independent QC, human approval and traceability — constraints that rule out the obvious approaches.
What technology exists?
Two finished products: FlashEDC (protocol analysis, eCRF design and EDC runtime) and FlashAnalysis (~2,500 automated tests, SDTM/ADaM/TLF, independent QC, Define-XML and reviewer guides).
How does it make money?
Fixed price per deliverable, a per-study software licence, and discounted paid pilots for the first customers. Pricing is scoped per study.
How does it reach customers?
Land with a fixed-price deliverable, expand to a per-study software licence, and scale through CRO and biostatistics partners who can white-label FlashAnalysis output.
Traction to date
Products built. Customers next.
Member of NVIDIA Inception and AWS Activate.
Two finished products
FlashEDC covers protocol analysis, eCRF design and its own EDC runtime. FlashAnalysis covers SDTM, ADaM, TLFs, independent QC and submission artifacts, with approximately 2,500 automated tests.
Pilot program open
Discounted paid pilots for the first customers, with a written path to a full-price per-study contract.
No customers yet
No case studies, customer logos or revenue. We state that plainly rather than letting a reader discover it during diligence.
Next step
Request the investor deck.
Tell us what you need to evaluate, and we will send the deck and the working technology rather than the narrative alone.

